

Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells

March 13 2023



Caspase inhibitors (CI) selectively protect normal cells from chemotherapyinduced apoptosis, without protection multidrug-resistant cancer cells. Flavopiridol (shown in red, as a cytotoxic/lethal drug) can induce apoptosis. The caspase inhibitor Z-DEVD-fmk (green) can block apoptosis but multidrugresistant cancer cells pump it out. Credit: *Oncotarget* (2023). DOI: 10.18632/oncotarget.28382

A new review paper titled "Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells" has been



published in Oncotarget.

Cancer therapy is limited by toxicity in normal cells and drug-resistance in cancer cells. In his latest review, Mikhail V. Blagosklonny, M.D., Ph.D., from Roswell Park Comprehensive Cancer Center, discusses the theory that cancer resistance to certain therapies can be exploited for protection of normal cells—simultaneously enabling the selective killing of resistant cancer cells by using antagonistic drug combinations, which include cytotoxic and protective drugs.

"No cancer cell, no matter how resistant it is, can survive chemotherapy in a cell culture. In the organism, however, therapy of cancer is limited by killing or damaging normal cells. Selective protection of normal cells from chemotherapy would increase the therapeutic window, improving the therapeutic outcome. Needless to say, reduction of side effects and better quality of life are very important for a <u>cancer patient</u>," states Dr. Blagosklonny.

Depending on the mechanisms of drug-resistance in cancer cells, the protection of normal cells can be achieved with inhibitors of CDK4/6, caspases, Mdm2, mTOR, and mitogenic kinases. When normal cells are protected, the selectivity and potency of multi-drug combinations can be further enhanced by adding synergistic drugs, in theory, eliminating the deadliest cancer clones with minimal side effects.

"I also discuss how the recent success of Trilaciclib may foster similar approaches into <u>clinical practice</u>, how to mitigate systemic side effects of chemotherapy in patients with <u>brain tumors</u> and how to ensure that protective drugs would only protect normal cells (not <u>cancer cells</u>) in a particular patient," adds Dr. Blagosklonny.

More information: Mikhail V. Blagosklonny, Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer



cells, Oncotarget (2023). DOI: 10.18632/oncotarget.28382

Provided by Impact Journals

Citation: Selective protection of normal cells from chemotherapy, while killing drug-resistant cancer cells (2023, March 13) retrieved 27 June 2024 from https://medicalxpress.com/news/2023-03-cells-chemotherapy-drug-resistant-cancer.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.